Iprasol is a preperation of Salbutamol & Ipratropium bromide.Salbutamol is a beta2-adrenergic agent which acts on airway smooth muscle resulting in relaxation. Ipratropium Bromide is a anticholinergic agent that works as a bronchodilator that dilates the bronchi in the lungs. Iprasol provides the simultaneous release of ipratropium bromide and salbutamol allowing the synergistic efficacy on the muscarinic and beta2-adrenergic receptors in the airways to cause bronchodilation which is superior to that provided by each single agent and with no potentiation of adverse events.
Iprasol HFA Inhalation aerosol
Inhaler puffs: 2 puffs 4 times a day. Patients may take additional puffs as required; however, the total number of puffs should not exceed 12 in 24 hours.
Inhaler solution: Inhalation solution in ampoule may be administered from a suitable nebuliser or an intermittent positive pressure ventilator.
Adults (including elderly): One ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.
Patients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations do not produce an adequate improvement.